Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Error-corrected DNA sequencing for MRD detection

Christopher Hourigan • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia General Leukemia

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the use of advanced error-corrected DNA sequencing for the highly sensitive detection of measurable residual disease (MRD). Next-generation sequencing introduces errors, which this ‘next next-generation sequencing’ method corrects for. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Christopher Hourigan

1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:50
Conditioning intensity and genomics: relapse after allogeneic transplant in MDS
Christopher Hourigan • 16 Jun 2020

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals